Hamilton Thorne licenses 3D imaging technology from ISee3D

TSX VENTURE: HTL

TORONTO , Dec. 18 /CNW/ - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announced it has reached an agreement with ISee3D Inc. to market their unique single camera, single lens, single chip 3D microscope technology currently under development. The agreement provides Hamilton Thorne with the exclusive rights to sell the ISee3D three-dimensional technology within the stem cell research and regenerative medical research markets.

"The 3D microscopic capability provides researchers a marked improvement over existing visualization systems available today," commented Dwight Romanica, Chairman and CEO of ISee3D. "In addition, the 3D microscope visualization is not limited to a white light illumination source like existing technologies, instead it functions across the entire UV spectrum which is essential to research that requires fluorescent tools for advanced imaging applications."

"This agreement expands our product pipeline by adding an innovative technology to our existing instrument base," said Meg Spencer , Chairman and CEO of Hamilton Thorne. "This novel 3D microscopic system is a cost-effective yet elegant solution to the ever-growing imaging needs of stem cell and advanced cell biology researchers in this exploding field of research. This agreement with ISee3D represents the first step of Hamilton Thorne's forward strategy to bring on board additional technologies to serve our customer base."

About Hamilton Thorne Ltd.

Hamilton Thorne's advanced laser systems and instruments are rapidly emerging as the dominant products to facilitate precise procedures in the stem cell research and fertility clinic markets. Hamilton Thorne's lead products, the ZILOS-tk and XYClone laser systems, attach to standard inverted microscopes and operate as robotic micro-surgeons, significantly reducing time and increasing efficiency in key in-vitro fertilization, stem cell, embryo, reproductive toxicology and living cell procedures.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, DuPont, Monsanto, Charles River Labs, Jackson Labs , Merck, Novartis, Pfizer, Oxford University and Cambridge.

About ISee3D Inc.

ISee3D Inc. (TSX-V: ICT) owns certain patented technology which provides for the capture of stereoscopic (3D) images through a single camera, single lens, single chip. The Company's technology has broad application in several markets including the home entertainment industry, consumer electronics, industrial and imaging devices of all sorts including microscopes, endoscopes as well as more sophisticated medical imaging systems.

Neither the exchange nor its regulation services provider (as that term is defined in the policies of the exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the company with the Canadian securities regulators, which filings are available at www.sedar.com.

%SEDAR: 00025407E

For further information: David Wolf, President, Hamilton Thorne Ltd., [phone], [email protected]; Ross Marshall, The Equicom Group, [phone] x238, [email protected]